Gastric cancer

What was the purpose of the CLASSIC clinical trial in gastric cancer?

After a D2 gastrectomy, patients randomized to observation versus adjuvant XELOX for 8 cycles –
showed a 3 year overall survival of 59% versus 74%

en_USEnglish